Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage (PACT-PCV)
The Added Value of Recombinant Tissue Plasminogen Activator (rtPA) in Pneumatic Displacement of Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy (PCV) With Concomitant Anti-VEGF Therapy: A Prospective Randomized Controlled Trial
The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).
The main questions it aims to answer are:
- Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
- Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?
Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.
The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.
Participants will:
- Undergo baseline eye examinations, vision testing, and retinal imaging.
- Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
- Follow the prescribed face-down positioning instructions for 3 days after treatment.
- Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Fang Zheng
- 電話番号:+86 18258499106
- メール:tjmuzxf@163.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
- An interval of ≤14 days between symptom onset and planned treatment.
- Willingness to participate in the study and provision of written informed consent.
Exclusion Criteria:
- Unwillingness to undergo pneumatic displacement (PD).
- A history of previous SMH.
- Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
- Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
- Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
- Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Triple PD (Anti-VEGF + Gas + rtPA)
Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
|
アクティブコンパレータ:Dual PD (Anti-VEGF + Gas)
Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of complete SMH displacement at 1 week after the procedure.
時間枠:1 week after procedure
|
No residual submacular hemorrhage in the foveal area on OCT. |
1 week after procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
時間枠:Within 1 month after the procedure
|
Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage. |
Within 1 month after the procedure
|
|
Incidence of severe postoperative complications, including retinal detachment
時間枠:Within 3 months after the procedure
|
Incidence of severe complications after the procedure, including retinal detachment. |
Within 3 months after the procedure
|
|
Change in best-corrected visual acuity (BCVA) at 6 months
時間枠:At 6 months after the procedure
|
Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis. |
At 6 months after the procedure
|
|
Macular anatomical outcomes at 6 months
時間枠:At 6 months after the procedure
|
Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis. |
At 6 months after the procedure
|
|
Number of anti-VEGF injections within 6 months after the procedure
時間枠:Within 6 months after the procedure
|
Total number of anti-VEGF injections administered within 6 months after the procedure. |
Within 6 months after the procedure
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2 0 2 6 - 0 6 5 2
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。